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Mineralocorticoid selectivity: Molecular and cellular aspects. 100,000 GRs per cell in the renal collecting duct and
Aldosterone acts in mineralocorticoid-sensitive cells by binding 10,000 MRs (Fig. 1).
to the mineralocorticoid receptor (MR). Because the MR dis- Because the MR displays the same affinity for aldoste-plays similar affinity for aldosterone and glucocorticoid hor-
rone and glucocorticoid hormones (about 0.5 to 1 nmol/L)mones and because these latter hormones are 100- to 1000-fold
and because these latter hormones are much more abun-more abundant than aldosterone in the plasma, mechanisms
are required to avoid permanent illicit occupancy of MR by dant (100- to 1000-fold) in the plasma, as compared with
glucocorticoid hormones. The main mechanism of mineralo- aldosterone (Fig. 1), it is obvious that some mechanisms
corticoid selectivity is enzymatic: the 11b hydroxysteroid dehy- are necessary to protect the MR against permanent occu-drogenase (HSD2) metabolizes glucocorticoid hormones into
pancy by glucocorticoid hormones [7, 8]. The main mech-derivatives with a low affinity for MR. The cell biology and
anism of mineralocorticoid selectivity depends on an en-regulation of HSD2 are reviewed in this article, as well as its
implications in human hypertension. Other factors play a role zyme [7, 8], 11b hydroxysteroid dehydrogenase (HSD),
in mineralocorticoid selectivity: the MR itself, the possibility which metabolizes cortisol (or corticosterone) into deriv-
to form homodimers (MR-MR), or heterodimers (with the atives (cortisone or dehydrocorticosterone) with little orglucocorticoid receptor). All of these cellular events participate
no affinity for MR (and GR as well). Thus, in the pres-to successive dynamic equilibriums, which allow fine tuning of
ence of HSD2, glucocorticoid hormones entering the celltranscriptional regulation of target genes, depending on the
target tissue and the hormonal status. are metabolized into 11-dehydro derivatives, and the
MR will be occupied by aldosterone as a function of its
plasma levels. In the absence of HSD2, the MR will be
It has long been known that corticosteroid hormones occupied by glucocorticoid hormones, and a permanent
are important for the maintenance of renal sodium reab- maximal sodium reabsorption will occur, without any
sorption, volemia, and blood pressure levels [1, 2]. The possible regulation by aldosterone. Such a situation is
mineralocorticoid hormone aldosterone promotes so- achieved when the enzyme is inhibited (hypertension
dium absorption in the renal distal nephron, the colon, caused by licorice ingestion) or genetically inactive [hy-
and the ducts of sweat and salivary glands. Glucocorti- pertension from the syndrome of apparent mineralocor-
coid hormones (cortisol in humans and corticosterone ticoid excess (AME)]. Several recent reviews have been
in rodents) also play an important role in the control of published on the subject [9–13].
ion reabsorption and the glomerular filtration rate. These 11b-hydroxysteroid dehydrogenase is coexpressed with
two hormones appear to act in a complex, distinct but MR and GR in renal aldosterone target cells [1], as
complementary pattern, which is not fully understood at illustrated in Figure 2. The MR is expressed selectively
the present time. Both bind intracellular receptors [1–3], in distal tubules and all along the collecting duct of the
the mineralocorticoid receptor (MR) and the glucocorti- rabbit [5, 6] and presumably in the mouse and in humans.
coid receptor (GR; Fig. 1). These receptors are members In the rat, however, MR expression extends to the corti-
of the superfamily of steroid hormone receptors that cal part of the thick ascending limb of Henle’s loop
act as ligand-dependent transcription factors [4]. They (TAL) [14]. HSD2 activity is high in distal tubules and
interact (directly or indirectly) with glucocorticoid re- collecting ducts of the rabbit, the mouse, and humans
sponse elements (GREs) in the promoter regions of reg- [15–21]. As was observed for MR, high HSD2 activity
ulated genes. GR is found in all aldosterone target cells extends to the TAL in rats [17, 18]. Besides renal coex-
and largely prevails over MR [5, 6]: There are about pression of MR and HSD2, other (putative) aldosterone
target tissues have been examined. Coexpression has
been documented, as expected, in sweat gland ducts [22]Key words: aldosterone, glucocorticoid hormones, mineralocorticoid
receptor, hypertension, 11bHSD2. and in the epithelium of distal colon [23]. In nonepithelial
cells, however, the situation is more complex. EvidenceÓ 2000 by the International Society of Nephrology
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Table 1. Comparison of mineralocorticoid receptor (MR) and
11b-dehydroxysteroid dehydrogenase-2 (HSD2) abundance
HSD2 activity
MR fmol/mg HSD2
receptor per cell protein/10 min MR ratio
Collecting
duct cells 10,000 50,000 5
Cardiac
myocytes 500–1000 70 0.1
The HSD2:MR ratio shows that cardiac myocytes MR are 50 times less pro-
tected (by HSD2) than collecting duct cells. Data are from [5, 18, 24–26].
for MR expression (and specific aldosterone binding)
has been provided in cardiac myocytes [24, 25] in the
rabbit and humans, and HSD2 activity has been evi-
denced in cardiac biopsies [25], at levels lower than those
observed in classic aldosterone cells such as the collecting
duct (Table 1) [26]. A comparison of the amounts ofFig. 1. Corticosteroid hormones, their plasma levels, affinity for miner-
alocorticoid receptors (MR) and glucocorticoid receptors (GR), and HSD2 available to protect MR in these two cell types
the number of receptors per aldosterone renal target cell. shows that the collecting duct cell MR is much better
protected by HSD2 that the cardiomyocyte MR (50 times
less efficient protection; Table 1). One can wonder
whether the cardiac MR-HSD2 system is sufficiently
tight to avoid binding of glucocorticoid hormones or
whether a significant proportion of MR may be occupied
by these latter hormones in vivo. In the brain (particu-
larly in the hippocampus), MR is expressed at high levels
[27–30], and there is a general agreement to consider
that HSD2 is very low in these tissues. This would mean
that MR in brain is permanently occupied by glucocorti-
coid hormones. However, it remains to be understood
why aldosterone and corticosterone exert distinct effects,
at least in some regions of the brain (article by de Kloet
et al, in this issue of Kidney International, p. 1329).
CELL BIOLOGY OF HSD2
11b-hydroxysteroid dehydrogenase (HSD) activity
has been studied for a long time and was characterized
first from liver microsomal preparations [31]. Initial clon-
ing revealed a form of the enzyme (named HSD1) that
was absent from mineralocorticoid-sensitive tissues [32].
The MR-protecting enzyme (named HSD2) was subse-
quently cloned [33, 34], and the differences between
these two forms are listed in Table 2. Several excellent
reviews have been published on this subject [11–13, 31,
35]. Here, we would like to emphasize some aspects of
the cell biology of HSD2. First, the enzyme HSD2 is
consistently found as a unidirectional enzyme (dehydro-
genase activity only); this unexpected behavior is unex-
Fig. 2. Schematic representation of mineralocorticoid receptors (MR), plained. Another peculiarity of the HSD2 is the wideglucocorticoid receptors (GR), and 11b-hydroxysteroid dehydrogenase-
range of substrate concentrations (0.1 nmol/L to 1 mmol/L)2 (HSD2) expression along the mammalian nephron. The black zone
represents the sites of high expression of GR, HSD2 (in rabbit, mouse, where the enzyme is active [26], which is not compatible
and humans), and MR [in rabbit; in the rat, the cortical portion of
with simple michaelian enzyme kinetics. This aspect hasHenle’s loop (tal) also expresses high levels of MR and HSD2]. Abbrevi-
ations are: pt, proximal tubule; dct, distal tubule; cd, collecting duct. been misregarded by most investigators, who considered
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Table 2. Differences between HSD1 and HSD2
HSD1 21% identity HSD2
Affinity for cortisol Low (100 nm) High (1–10 nm)
Cofactor NADP NAD
Enzymatic properties Dehydrogenase and reductase Dehydrogenase
Expression Ubiquitous Aldosterone-sensitive cells
Function Local regulation of glucocorticoid action Protection of MR
Molecular wt 34 kD (290 aa) 44 kD (400 aa)
(
Glycosylation Important for activity Not required for activity
Abbreviations are: HSD, 11b-hydroxysteroid dehydrogenase; NAD, nicotinamide adenine dinucleotide; NADP, nicotinamide adenine dinucleotide phosphate;
MR, mineralocorticoid receptor.
it as a michaelian enzyme [12, 13, 19, 21]. However, its 13, 39]. The syndrome of apparent mineralocorticoid
excess (AME) is a rare form of congenital hypertension,functioning may be more complex (nonmichaelian), in-
volving a series of equilibriums between multimers of the with severe hypertension, hypokalemia, and low levels of
renin and aldosterone. Genetic analyses of the kindredsenzyme (for example, dimers and tetramers). It has been
suggested that HSD2 exists as a dimer, and other members showed mutations in HSD2 as being responsible for inac-
tivation of the enzyme [13, 39]; in these children, cortisolof the short-chain alcohol dehydrogenase (SCAD) super-
family also function as multimers [13]. The SCAD super- permanently occupies the MR and promotes sustained
sodium reabsorption. A mouse model for AME has beenfamily, to which both HSD1 and HSD2 belong, includes
more than 100 members; the three-dimensional struc- obtained recently by inactivation of HSD2 using homolo-
gous recombination [40]; these knockout mice developtures of some of them have been solved by x-ray crystal-
hypertension, hypotonic polyuria, and low levels of plasmalography. Interestingly, the 3a-20b-HSD is a tetramer,
aldosterone. The enzyme may also be inhibited by glycyr-and it has been suggested that the 11b-HSD enzymes
rhetinic acid, the active metabolite of licorice [12, 13].exhibit protein folding very similar to those of 3a-20b-
Hypertension, which develops after chronic ingestion ofHSD and 17b-HSD1 [13, 35].
licorice, is due to HSD2 inhibition, and normalizationHSD2 has a hydrophobic N-terminal domain that is
of blood pressure occurs after licorice withdrawal.considered important for anchoring in the membrane of
Other situations (for example, subgroups of essentialthe endoplasmic reticulum [13]. However, it has been
hypertension) may be reminiscent of abnormal HSD2shown that deletion of this region does not modify its
activity, although definite information is actually lackingactivity and does not release the enzyme in the cytoplasm
[12, 13], probably because of the difficulty to estimate[13, 36]. Elegant studies with green fluorescent protein
the in vivo activity of the enzyme. A good estimate of(GFP)-tagged HSD2 transfected in Chinese hamster
the efficiency of the enzyme can be obtained by theovary (CHO) cells indicated that HSD2 is localized in
plasma or urine ratio of the THE/THF, that is, the tetra-the endoplasmic reticulum [37], whereas other studies
hydro-derivatives of cortisone (E) and cortisol (F). Ab-[13, 23] found nuclear localization of the enzyme, as dem-
normally low ratios have been reported in patients withonstrated by immunolocalization. Further studies are
AME [39], but a search for milder involvement of theneeded to clarify the subcellular localization of HSD2.
enzyme deficiency in essential hypertension has beenLittle information is available on putative post-transla-
disappointing using this test (as well as the search fortional modifications of HSD2. Despite the presence of
mutations of HSD2). It should be taken into consider-one potential N-glycosylation site, such a phenomenon
ation that the ratio of reduced versus dehydrogenateddoes not seem to be effective, since the molecular weight
cortisol metabolites indeed depends on the activity ofof HSD2 is not influenced by tunicamycin or N-glycosi-
renal HSD2 (dehydrogenase) as well as the hepaticdase treatment [13, 38]. Other post-translational modifi-
HSD1, which is a bidirectional enzyme (dehydrogenasecations, such as phosphorylation or myristoylation may
and reductase). Thus, a partial defect in renal HSD2exist, but experimental investigations have not yet been
(leading to abnormal sodium reabsorption) may beperformed to test these possibilities.
masked in blood or in urine by a partial compensation by
hepatic HSD1. In order to gain more precise information
11b-HYDROXYSTEROID DEHYDROGENASE 2 from human aldosterone target cells, a microassay of
AND HYPERTENSION HSD2 activity has been developed using sweat gland
ducts [22]. These ducts may be obtained by microdissec-Clinical evidence for the major role of HSD2 came
from observations of some forms of arterial hyperten- tion from skin biopsies and allow an accurate measure-
ment of the catalytic activity of the enzyme. Sweat glandsion, where the enzyme appeared to be abnormal [12,
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ducts also express the MR, and their level of HSD2 when MR is bound to glucocorticoid hormones (dis-
activity is similar to that of the collecting duct [22]. A cussed in the article by M.E. Oblin in this issue of Kidney
search for an abnormal function of HSD2 in hypertensive International). Such distinct properties of MR, de-
patients is currently under investigation using this ap- pending on its ligand, ultimately modify its transactiva-
proach. tion capacities [45, 48]. As already noted by Arriza et
al, MR-induced transactivation is much more efficient
in the presence of aldosterone, the half maximal trans-REGULATION OF 11b-HYDROXYSTEROID
activation occurring at 5 3 10210 mol/L with aldosteroneDEHYDROGENASE 2
and 5 3 1028 mol/L with dexamethazone [48]. It should
An important issue is to know whether or not HSD2 be noted that this kind of study is usually performed
is subject to regulation. Surprisingly little information is using a classic GRE [from mouse mammary tumor virus
available on this point. Some studies showed inhibition (MMTV)] linked to a reporter gene. It will be interesting
of the enzyme by several natural components. Besides to determine whether the aldosterone-bound MR (and
glycyrrhetinic acid and carbenoxolone, inhibitors were the cortisol-bound MR) behaves similarly on the pro-
found in grapefruit juice, cotton seeds, and others [13]. moters of endogenously regulated genes, such as early
Some bile acids also reduce the activity of HSDs, and aldosterone-induced proteins (most of which have not
recently it has been suggested that endogenous inhibitors yet been characterized).
of HSD2, named GALF (for glycyrrhetinic acid-like fac- Despite the remarkable efficiency of HSD2 to metabo-
tor) exist in the plasma and may be increased in essential lize most of the glucocorticoid hormones entering the
hypertension (discussed in the article by D. Morris in this aldosterone target cell, it is likely that some glucocorti-
issue of Kidney International). The search for stimulatory coids escape this inactivating mechanism and thus are
factors has been scarce. In vivo changes in corticosteroid able to occupy MR (and GR) to some extent [1, 9]. This
status in rats (deprivation by adrenalectomy and selec- is probably a very significant regulatory pathway in these
tive treatment by aldosterone or glucocorticoid hormones) cells because it may allow the variation of the proportion
showed a moderate increase [41] or no change [26] in of each receptor bound to each ligand. Furthermore, be-
HSD activity. No effect of corticosteroid hormones was cause of the possibility to form homodimers (MR-MR or
evidenced on HSD2 transcripts. Protein kinase A may GR-GR) or heterodimers (MR-GR), which have distinct
be involved in the regulation of HSD2, since arginine- transactivation properties [49], transcription of target
vasopressin (or cAMP) stimulates HSD2 activity in vitro
genes can be controlled in a very specific pattern, which
in isolated cortical collecting ducts [41]. Interestingly,
will vary with the corticosteroid status [1, 9]. Interesting
such an effect requires aldosterone; the effect is observed
information should be provided by systematic analysis
only in tubules from normal animals or adrenalecto-
of the transactivation efficiency of these homodimers/
mized rats receiving a substitutive aldosterone treat-
heterodimers in the presence of varying proportions ofment. Thus, it appears that the two main hormones that
aldosterone and glucocorticoid hormones as ligands.exert a fine tuning of renal sodium reabsorption [42]—
Because inactivation of the bulk of glucocorticoid hor-aldosterone and vasopressin—act coordinately to en-
mones by HSD2 precedes the formation of liganded ho-hance HSD2 activity, thereby reinforcing mineralocorti-
modimers/heterodimers, any change in HSD2 activitycoid selectivity.
will likely modify this series of dynamic equilibriums
by affecting the downstream steps, that is, the relative
OTHER MECHANISMS OF proportion of receptors occupied by each ligand [9].
MINERALOCORTICOID SELECTIVITY Transcription of target genes will also depend on inter-
actions between MR (or MR-GR) and other transcriptionThe MR itself has intrinsic properties that discriminate
factors [9] such as tissue-specific factors, cAMP responsebetween aldosterone and glucocorticoid hormones [43–46].
element-binding proteins, or members of the Jun-FosIndeed, the MR displays the same apparent affinity for
family. Such interactions have not yet been fully docu-these ligands. However, it is important to remember that
mented, but they are highly probable in view of thethe affinity constant at equilibrium (Kd) is the ratio of
differential effects of aldosterone in distinct tissues. ForKon and Koff; if both are increased (for example, in the
example, aldosterone up-regulates the transcripts encod-case of glucocorticoid hormones binding to the MR), the
ing for the sole a subunit of the epithelial sodium channelapparent affinity is unchanged. It has been shown that
(ENaC) in renal collecting duct cells (b and g unchanged),the interaction of the MR with aldosterone has a more
while affecting the b and g subunits (not a) of ENaC inprolonged half-life [45], as compared with glucocorticoid
the epithelial cells of the distal colon [50]. Along thehormone–MR complexes, reflecting distinct molecular
same line, aldosterone and vasopressin cooperate to up-ligand–MR interactions. The compaction of the MR
bound to aldosterone [47] differs from that occurring regulate ENaC subunits transcripts in kidney cells, with
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